Adenoid Cystic Carcinoma Treatment News and Symptoms Information

What is an Adenoid Cystic Carcinoma (ACC)?

(Symptoms, Causes & Treatment)

According to the Oral Cancer Foundation, adenoid cystic carcinoma (ACC) is an uncommon form of malignant neoplasm that arises within secretory glands, most commonly the major and minor salivary glands of the head and neck. Other sites of origin include the trachea, lacrimal gland, breast, skin, and vulva. This neoplasm is defined by its distinctive histologic appearance.

It is the third most common malignant salivary gland tumor overall (after mucoepidermoid carcinoma and polymorphous low grade adenocarcinoma). It represents 28% of malignant submandibular gland tumors, making it the single most common malignant salivary gland tumor in this region. Patients may survive for years with metastases because this tumor is generally well-differentiated and slow growing.

See below for updated news and information regarding Adenoid Cystic Carcinoma including new medical research, treatment options and advancements. 

Latest Adenoid Cystic Carcinoma Treatment News and Research

Scientists describe lab technique with potential to change medicine

Medical XpressJan 26, 2017
Yale scientists discovered Notch1 and SOX10 are potential new therapeutic targets of adenoid cystic carcinoma. Researchers at Fox Chase …

Distinct, Aggressive Subgroup of ACC Identified With Activating NOTCH1 Mutations

NOTCH1 mutations have been found to define an aggressive subgroup of patients with adenoid cystic carcinomas (ACC), with a corresponding pattern of metastatic spread, according to the results of a recent study from the Journal of Clinical Oncology.

This distinct, aggressive phenotype is characterized by solid histology, liver and bone metastasis, poor prognosis, and possible responsiveness to Notch1 inhibitors. 


Phase I trial shows that a drug that inhibits the Notch signalling process is active in a range of advanced cancers

A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumors. Importantly, it has been able to do this in rare cancers that are less well-studied such as adenoid cystic carcinoma.


Drug target found in rare, lethal glandular cancer

Using a novel cell culture approach, researchers have discovered critical vulnerabilities in adenoid cystic carcinoma (ACC), a rare and lethal glandular cancer with a high recurrence rate and few treatment options.


healthcare careers

science careers

If you have experience dealing with this disease or condition (especially with regard to symptoms, diagnosis, causes or treatment), please share below: